Clinical-stage biopharmaceutical company Vir Biotechnology Inc (Nasdaq:VIR) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer.
VIR-5500 is being co-developed by Vir Biotechnology and Astellas Pharma (TYO:4503) under a global strategic collaboration.
The therapy is being evaluated in a Phase 1 study across six dose-expansion cohorts, including monotherapy and combination regimens targeting different stages and treatment settings of prostate cancer.
Earlier Phase 1 data showed that VIR-5500 was generally well tolerated and demonstrated promising anti-tumour activity in patients with metastatic castration-resistant prostate cancer.
Fast Track designation is intended to facilitate and expedite development and review of treatments for serious conditions with unmet medical needs.
Phase 3 trials for VIR-5500 are anticipated to begin in 2027.
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
GlycoNex submits marketing authorisation application for denosumab biosimilar to Japanese regulator
Akeso publishes ivonescimab Phase II study results in Nature Medicine
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Minghui Pharmaceutical licenses IGF-1R antibody to ASKA Pharmaceutical in Japan